With regards to his pioglitazone use, he had no history of heart failure, and his ALT level was acceptable at the time of discharge at 25 U/L. Signs and symptoms of heart failure were reviewed with ...

Despite these limitations, the findings suggest that GLP-1 receptor agonists may provide important limb, cardiovascular, and renal protection in patients with diabetes and prior MALEs, supporting ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most adults with type 2 diabetes receiving an ...

Association driven by fewer major amputations ...

Severe Hypoglycemia Ups Cardiovascular Risk in Diabetes Two studies demonstrate no difference versus placebo for saxagliptin, alogliptin. For patients with type 2 diabetes, treatment with the ...

In patients with diabetes and a prior major adverse limb event, GLP-1s were associated with better outcomes compared with DPP ...

Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Find out how GLP-1 RAs reduce limb, heart, and kidney risks in high-risk diabetes patients. Keep reading to learn more.